Euroasian journal of hepato-gastroenterology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  14 (2024)
Volume  13 (2023)
Volume  12 (2022)
Volume  11 (2021)
Volume  10 (2020)
Volume  9 (2019)
Volume  8 (2018)
Volume  7 (2017)
Volume  6 (2016)
Volume  5 (2015)
Volume  4 (2014)
Volume  3 (2013)
Volume  2 (2012)
Volume  1 (2011)
Related articles

VOLUME 14 , ISSUE 2 ( July-December, 2024 ) > List of Articles

Original Article

Perihilar and Intrahepatic Cholangiocarcinoma after Resection: Clinicopathological Characteristics, Outcomes, and Implications for Addition of Chemoradiotherapy

Puja Sahai, Archana Rastogi, Ajay Gupta, Nilesh S Patil, Namita Sharma, Nihar Mohapatra, Archana Sharma, Karthika Rudrakumar, Ankur Jindal, Amar Mukund, Guresh Kumar, Viniyendra Pamecha, Hanuman P Yadav

Keywords : Biliary tract cancers, Biliary tract neoplasms, Chemoradiation, Chemotherapy, Cholangiocarcinoma, Radiotherapy, Resection, Stereotactic body radiotherapy

Citation Information : Sahai P, Rastogi A, Gupta A, Patil NS, Sharma N, Mohapatra N, Sharma A, Rudrakumar K, Jindal A, Mukund A, Kumar G, Pamecha V, Yadav HP. Perihilar and Intrahepatic Cholangiocarcinoma after Resection: Clinicopathological Characteristics, Outcomes, and Implications for Addition of Chemoradiotherapy. Euroasian J Hepatogastroenterol 2024; 14 (2):134-144.

DOI: 10.5005/jp-journals-10018-1440

License: CC BY-NC 4.0

Published Online: 27-12-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Background: The purpose of the present study was to evaluate clinicopathological characteristics, patterns of recurrence, survival outcomes, and implications for the addition of chemoradiotherapy for patients with resected perihilar and intrahepatic cholangiocarcinoma (CCA). Materials and methods: For the present retrospective study, we identified 38 and 10 patients with resected perihilar and intrahepatic CCA. In perihilar CCA, adjuvant treatment was given as chemotherapy (n = 13) or chemoradiotherapy (n = 10). In intrahepatic CCA, neoadjuvant treatment was given with transarterial chemoembolization (TACE, n = 1) or chemotherapy plus stereotactic body radiation therapy (SBRT, n = 1), and adjuvant treatment was given to 7 patients with chemotherapy or chemoradiotherapy. Results: In perihilar CCA, preoperative biliary drainage procedures were performed in 27 out of 30 patients with jaundice. The adjacent liver showed secondary sclerosing cholangitis (n = 5) and fibrosis (n = 19). Locoregional recurrence involved the hepaticojejunostomy anastomotic site and lymph nodes. In intrahepatic CCA, the adjacent liver revealed cirrhosis (n = 1), secondary sclerosing cholangitis (n = 1), and fibrosis (n = 6). The sites of recurrence were in the remnant liver and lymph nodes (n = 6). In perihilar CCA, the median overall survival (OS) and disease-free survival (DFS) rates were 30.1 months (95% CI: 22.9–37.4) and 15.1 months (95% CI: 9.74–20.5), respectively. The 2-year and 3-year OS were 60.5% and 44.7%, respectively. Multivariate analysis revealed a significant association of no adjuvant treatment with decreased DFS (p = 0.004), HR 4.03 (95% CI: 1.57–10.4). Recurrence showed an unfavorable association with OS (p = 0.056), HR 2.90 (95% CI: 0.98–8.66). In intrahepatic CCA, the median OS and DFS rates were 41.2 months (95% CI: 13.5–68.9) and 10.8 months (95% CI: 1.98–19.6), respectively. The 2-year and 3-year OS were 66.7% and 53.3%, respectively. The patient with multiple intrahepatic CCA lesions and treated with neoadjuvant chemotherapy and SBRT showed partial pathological necrosis after resection and was disease-free at 3.5 years. Conclusions: The present study showed the effectiveness of the combination of chemoradiotherapy with resection in improving locoregional disease control and survival in patients with perihilar and intrahepatic CCA.

PDF Share
  1. Ghiringhelli F, Jooste V, Manfredi S, et al. Biliary tract cancers have distinct epidemiological patterns and clinical characteristics according to tumour site. HPB 2023;25(6):693–703. DOI: 10.1016/j.hpb.2023.02.016.
  2. Patkar S, Gupta V, Khobragade K, Goel M. The reality of cholangiocarcinoma in India- real world data from a tertiary referral centre. HPB 2022;24(9):1511–1518. DOI: 10.1016/j.hpb.2022.03.007.
  3. Dee EC, Freret ME, Horick N, et al. Patterns of failure and the need for biliary intervention in resected biliary tract cancers after chemoradiation. Ann Surg Oncol 2020;27(13):5161–5172. DOI: 10.1245/s10434-020-08967-9.
  4. Tian Y, Wen N, Li B, et al. A meta-analysis of prognostic factors for early recurrence in perihilar cholangiocarcinoma after curative-intent resection. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2023;49(11):106982. DOI: 10.1016/j.ejso.2023.07.008.
  5. Kamarajah SK, Al-Rawashdeh W, Parente A, et al. Adjuvant chemotherapy for perihilar cholangiocarcinoma: A population-based comparative cohort study. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2022;48(6):1300–1308. DOI: 10.1016/j.ejso.2021.12.002.
  6. Wang G, Wang Q, Fan X, et al. The significance of adjuvant therapy for extrahepatic cholangiocarcinoma after surgery. Cancer Manag Res 2019;11:10871–10882. DOI: 10.2147/CMAR.S224583.
  7. Shi X qi, Zhang J yu, et al. Role of adjuvant (chemo)radiotherapy for resected extrahepatic cholangiocarcinoma: A meta-analysis. J Zhejiang Univ-Sci B 2020;21(7):549–559. DOI: 10.1631/jzus.B1900691.
  8. Gkika E, Hawkins MA, Grosu AL, et al. The evolving role of radiation therapy in the treatment of biliary tract cancer. Front Oncol 2020;10:604387. DOI: 10.3389/fonc.2020.604387.
  9. Sahai P, Kumar S. External radiotherapy and brachytherapy in the management of extrahepatic and intrahepatic cholangiocarcinoma: Available evidence. Br J Radiol 2017;90(1076):20170061. DOI: 10.1259/bjr.20170061.
  10. Edge S, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York: Springer-Verlag; 2010.
  11. Amin MB, Edge S, Greene F, et al, editors. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing; 2017.
  12. Song Y, Cai M, Li Y, et al. The focus clinical research in intrahepatic cholangiocarcinoma. Eur J Med Res 2022;27(1):116. DOI: 10.1186/s40001-022-00741-9.
  13. Yoon SJ, Park S, Kim H, et al. The oncologic implications of tumor multiplicity in intrahepatic cholangiocarcinoma: Its prognostic value might be underestimated. Cancer Res Treat 2023;55(3):948–955. DOI: 10.4143/crt.2023.290.
  14. Rogacka NA, Benkö T, Saner FH, et al. Lymph node staging in perihilar cholangiocarcinoma: The key to the big picture. Curr Oncol Tor Ont 2023;30(6). DOI: 10.3390/curroncol30060438.
  15. Jiang JH, Fang DZ, Hu YT. Influence of surgical margin width on survival rate after resection of intrahepatic cholangiocarcinoma: A systematic review and meta-analysis. BMJ Open 2023;13(5):e067222. DOI: 10.1136/bmjopen-2022-067222.
  16. Alaimo L, Moazzam Z, Endo Y, et al. The application of artificial intelligence to investigate long-term outcomes and assess optimal margin width in hepatectomy for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2023;30(7):4292–4301. DOI: 10.1245/s10434-023-13349-y.
  17. Jeong H, Kim KP, Jeong JH, et al. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial. Hepatol Baltim Md 2023;77(5):1540–1549. DOI: 10.1097/HEP.0000000000000046.
  18. Laurenzi A, Brandi G, Greco F, et al. Can repeated surgical resection offer a chance of cure for recurrent cholangiocarcinoma? Langenbecks Arch Surg 2023;408(1):102. DOI: 10.1007/s00423-023-02839-y.
  19. Wang XY, Zhu WW, Lu L, et al. Development and validation of a mutation-annotated prognostic score for intrahepatic cholangiocarcinoma after resection: A retrospective cohort study. Int J Surg Lond Engl 2023;109(11):3506–3518. DOI: 10.1097/JS9.0000000000000636.
  20. Hassan H, Chakrabarti S, Zemla T, et al. Impact of perioperative chemotherapy on survival in patients with cholangiocarcinoma undergoing curative resection. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2023;49(11):106994. DOI: 10.1016/j.ejso.2023.106994.
  21. Guo YL, Guo JX, Zhao JG, et al. Analysis of the efficacy and factors influencing survival of adjuvant radiotherapy for stage II-III biliary tract carcinoma. World J Surg Oncol 2023;21(1):339. DOI: 10.1186/s12957-023-03209-0.
  22. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 2015;33(24):2617–2622. DOI: 10.1200/JCO.2014.60.2219.
  23. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20(5):663–673. DOI: 10.1016/S1470-2045(18)30915-X.
  24. Liu QQ, Shi X de, Ye YF, et al. Real-world experience of postoperative adjuvant chemoimmunotherapy in patients with perihilar cholangiocarcinoma at high risk of recurrence. Cancer Immunol Immunother CII 2023;72(6):1753–1761. DOI: 10.1007/s00262-022-03362-7.
  25. Quaresima S, Melandro F, Giovanardi F, et al. New insights in the setting of transplant oncology. Med Kaunas Lith 2023;59(3):568. DOI: 10.3390/medicina59030568.
  26. Parente A, Kamarajah SK, Baia M, et al. Neoadjuvant chemotherapy for intrahepatic, perihilar, and distal cholangiocarcinoma: A national population-based comparative cohort study. J Gastrointest Surg Off J Soc Surg Aliment Tract 2023;27(4):741–749. DOI: 10.1007/s11605-023-05606-y.
  27. Mason MC, Massarweh NN, Tzeng CWD, et al. Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? Implications from the neoadjuvant experience. Ann Surg Oncol 2021;28(11):6725–6735. DOI: 10.1245/s10434-020-09536-w.
  28. Ayabe RI, Paez-Arango N, Estrella JS, et al. Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma – Does pathologic response mean better outcomes? HPB 2023;25(4):472–480. DOI: 10.1016/j.hpb.2023.01.011.
  29. Sutton TL, Billingsley KG, Walker BS, et al. Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. Am J Surg 2021;221(6):1182–1187. DOI: 10.1016/j.amjsurg.2021.02. 029.
  30. Maithel SK, Keilson JM, Cao HST, et al. NEO-GAP: A single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma. Ann Surg Oncol 2023;30(11):6558–6566. DOI: 10.1245/s10434-023-13809-5.
  31. Yang Z, Jiang X. Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: A systematic review and meta-analysis. BMC Gastroenterol 2023;23(1):122. DOI: 10.1186/s12876-023-02754-y.
  32. Gyoten K, Kuriyama N, Maeda K, et al. Safety and efficacy of neoadjuvant chemotherapy based on our resectability criteria for locally advanced perihilar cholangiocarcinoma. Langenbecks Arch Surg 2023;408(1):261. DOI: 10.1007/s00423-023-03000-5.
  33. Zhang XX, Ma HB, Li TH, et al. Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex 2023;25(3):731–738. DOI: 10.1007/s12094-022-02979-5
  34. Liu MY, Lo CH, Lin CS, et al. Stereotactic ablative radiotherapy for patients with unresectable or medically inoperable cholangiocarcinoma. Tumori 2017;103(3):236–241. DOI: 10.5301/tj.5000588.
  35. Sakata J, Takizawa K, Miura K, et al. Rational extent of regional lymphadenectomy and the prognostic impact of the number of positive lymph nodes for perihilar cholangiocarcinoma. Ann Surg Oncol 2023;30(7):4306–4317. DOI: 10.1245/s10434-023-13 361-2.
  36. Endo Y, Moazzam Z, Lima HA, et al. The impact of tumor location on the value of lymphadenectomy for intrahepatic cholangiocarcinoma. HPB 2023;25(6):650–658. DOI: 10.1016/j.hpb.2023.02.013.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.